Budesonide 1mg orodispersible tablet twice daily ( DrugBank: Budesonide )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
98	Eosinophilic gastrointestinal disease	2

98. Eosinophilic gastrointestinal disease

---

Clinical trials : 171 /  Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02493335 (ClinicalTrials.gov)	January 15, 2016	7/7/2015	Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis	Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis	Eosinophilic Esophagitis	Drug: Budesonide 0.5mg orodispersible tablet twice daily;Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily	Dr. Falk Pharma GmbH	NULL	Completed	18 Years	75 Years	All	204	Phase 3	Germany
2	NCT02434029 (ClinicalTrials.gov)	November 11, 2015	30/4/2015	Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis	Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis	Eosinophilic Esophagitis	Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily	Dr. Falk Pharma GmbH	NULL	Completed	18 Years	75 Years	All	88	Phase 3	Germany